A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial

American Journal of Psychiatry

Volumn 176, Issue 11, 2019, Pages 923-930

  Dakwar, Elias ^a   Nunes, Edward V ^a   Hart, Carl L ^a,b   Foltin, Richard W ^a   Mathew, Sanjay J ^c   Carpenter, Kenneth M ^a   Choi, C J ^a   Basaraba, Cale N ^a   Pavlicova, Martina ^b   Levin, Frances R ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University ^*  (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; MIDAZOLAM; AMINO ACID RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; BEHAVIOR MODIFICATION; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG CRAVING; DRUG INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HOSPITAL CARE; HUMAN; MALE; MINDFULNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SINGLE DRUG DOSE; TREATMENT OUTCOME; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES;

COCAINE-RELATED DISORDERS; COMBINED MODALITY THERAPY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDAZOLAM; MIDDLE AGED; MINDFULNESS; TREATMENT OUTCOME;

EID: 85074377315     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2019.18101123     Document Type: Article

References (40)

1. John WS, Wu L-T: Trends and correlates of cocaine use and cocaine use disorder in the United States from 2011 to 2015. Drug Alcohol Depend 2017; 180:376-384
2. Volkow ND, Morales M: The brain on drugs: from reward to addiction. Cell 2015; 162:712-725
3. Goldstein RZ, Volkow ND: Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159:1642-1652
4. Bespalov AY, Zvartau EE, Balster RL, et al: Effects of N-methyl-Daspartate receptor antagonists on reinstatement of cocaine-seeking behavior by priming injections of cocaine or exposures to cocaine-associated cues in rats. Behav Pharmacol 2000; 11:37-44
5. Popik P, Wrobel M, Rygula R, et al: Effects of memantine, an NMDA receptor antagonist, on place preference conditioned with drug and nondrug reinforcers in mice. Behav Pharmacol 2003; 14: 237-244
6. Collins ED, Ward AS, McDowell DM, et al: The effects of memantine on the subjective, reinforcing, and cardiovascular effects of cocaine in humans. Behav Pharmacol 1998; 9:587-598
7. Price KL, McRae-Clark AL, Saladin ME, et al: D-Cycloserine and cocaine cue reactivity: preliminary findings. Am J Drug Alcohol Abuse 2009; 35:434-438
8. Bisaga A, Aharonovich E, Cheng WY, et al: A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend 2010; 111:97-104
9. Sanacora G, Schatzberg AF: Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 2015; 40:259-267
10. Dakwar E, Hart CL, Levin FR, et al: Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized crossover trial. Mol Psychiatry 2017; 22:76-81
11. Dakwar E, Levin F, Foltin RW, et al: The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry 2014; 76: 40-46
12. Dakwar E, Nunes EV: New directions in medication-facilitated behavioral treatment for substance use disorders. Curr Psychiatry Rep 2016; 18:64
13. Bowen S, Chawla N, Collins SE, et al: Mindfulness-based relapse prevention for substance use disorders: a pilot efficacy trial. Subst Abus 2009; 30:295-305
14. Brewer JA, Sinha R, Chen JA, et al: Mindfulness training and stress reactivity in substance abuse: results from a randomized, controlled stage I pilot study. Subst Abus 2009; 30:306-317
15. Hoppes K: The application of mindfulness-based cognitive interventions in the treatment of co-occurring addictive and mood disorders. CNS Spectr 2006; 11:829-851
16. Marchand WR: Neural mechanisms of mindfulness and meditation: evidence from neuroimaging studies. World J Radiol 2014; 6: 471-479
17. Kang D-H, Jo HJ, Jung WH, et al: The effect of meditation on brain structure: cortical thickness mapping and diffusion tensor imaging. Soc Cogn Affect Neurosci 2013; 8:27-33
18. Hölzel BK, Carmody J, Vangel M, et al: Mindfulness practice leads to increases in regional brain gray matter density. Psychiatry Res 2011; 191:36-43
19. Brewer JA, Garrison KA: The posterior cingulate cortex as a plausible mechanistic target of meditation: findings from neuroimaging. Ann N Y Acad Sci 2014; 1307:19-27
20. Brefczynski-Lewis JA, Lutz A, Schaefer HS, et al: Neural correlates of attentional expertise in long-term meditation practitioners. Proc Natl Acad Sci USA 2007; 104:11483-11488
21. Fingelkurts AA, Fingelkurts AA, Kallio-Tamminen T: Long-term meditation training induced changes in the operational synchrony of default mode network modules during a resting state. Cogn Process 2016; 17:27-37
22. Scheidegger M, Walter M, Lehmann M, et al: Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One 2012; 7:e44799
23. Creswell JD,Taren AA,Lindsay EK,et al: Alterationsinresting-state functional connectivity link mindfulness meditation with reduced interleukin-6: a randomized controlled trial. Biol Psychiatry 2016; 80:53-61
24. Sheehan DV, Lecrubier Y, Sheehan KH, et al: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20):22-33
25. Williams JBW: A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988; 45:742-747
26. Bernstein EM, Putnam FW: Development, reliability, and validity of a dissociation scale. J Nerv Ment Dis 1986; 174:727-735
27. First MB, Williams JBL, Spitzer RL, et al: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). New York, New York State Psychiatric Institute, Biometrics Research, 2007
28. Stahl S: Essential Psychopharmacology: Neuroscientific Basis and Clinical Applications, 3rd ed. Cambridge, UK, Cambridge University Press, 2008
29. Bowen S, Chawla N, Marlatt GA: Mindfulness-Based Relapse Prevention for Addictive Behaviors: A Clinician's Guide. New York, Guilford Press, 2010
30. Bremner JD, Krystal JH, Putnam FW, et al: Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 1998; 11:125-136
31. Robinson SM, Sobell LC, Sobell MB, et al: Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav 2014; 28:154-162
32. Krupitsky EM, Grinenko AY: Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs 1997; 29:165-183
33. Krupitsky E, Burakov A, Romanova T, et al: Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat 2002; 23:273-283
34. Dakwar E, Anerella C, Hart CL, et al: Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend 2014; 136:153-157
35. Lehmann M, Seifritz E, Henning A, et al: Differential effects of rumination and distraction on ketamine induced modulation of resting state functional connectivity and reactivity of regions within the default-mode network. Soc Cogn Affect Neurosci 2016; 11: 1227-1235
36. Kraguljac NV, Frölich MA, Tran S, et al: Ketamine modulates hippocampal neurochemistry and functional connectivity: a combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteers. Mol Psychiatry 2017; 22:562-569
37. Luckenbaugh DA, Niciu MJ, Ionescu DF, et al: Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord 2014; 159:56-61
38. Berglind WJ, See RE, Fuchs RA, et al: A BDNF infusion into the medial prefrontal cortex suppresses cocaine seeking in rats. Eur J Neurosci 2007; 26:757-766
39. Williams NR, Heifets BD, Blasey C, et al: Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 2018; 175:1205-1215
40. Short B,Fong J,Galvez V, et al: Side-effectsassociated with ketamine use in depression: a systematic review. Lancet Psychiatry 2018; 5: 65-78